Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT04477486 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Ibrutinib
DRUG: Venetoclax

Sponsor

AbbVie